Breast cancer cells that make too much HER2/ERBB2 spread faster but are also more likely to respond to HER-specific chemo and immunotherapy, with mutations in MUC4 known to associate with upregulated ERBB proteins, observed in the Indian cohort (Mill et al., 2011). Here, ERBB2 is linked to breast cancer.